Exclusive

Publication

Byline

Pharma Q2 preview: Steady growth despite US sales pressure, GST rate cuts

New Delhi, Oct. 21 -- Indian drugmakers are expected to post steady earnings growth for the quarter ended 30 September, gaining from continued traction across global markets, although domestic sales m... Read More


Mint Explainer: The US Biosecure Act is back. How will Indian contract manufacturers benefit?

New Delhi, Oct. 13 -- A piece of US legislation from 2024 that aimed to curb American companies' ties to certain Chinese biotechs has made a comeback - and Indian contract drug manufacturers are prime... Read More


Pharma deals are surging. But the biggest drugmakers are holding back.

New Delhi, Oct. 9 -- Dealmaking in India's pharma sector has surged over the past two years as companies seek to beef up their portfolios and reduce reliance on the US market. Yet, some of the country... Read More


Mint Explainer | Does India have a cough syrup problem?

New Delhi, Oct. 5 -- Two Indian drugmakers have come under regulatory scrutiny after cough syrups made by them were linked to a number of child deaths in Madhya Pradesh and Rajasthan. The central drug... Read More